We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Astrazeneca (AZN) Stock Slides as Market Rises: Facts to Know Before You Trade
Read MoreHide Full Article
In the latest close session, Astrazeneca (AZN - Free Report) was down 1.38% at $72.66. The stock trailed the S&P 500, which registered a daily gain of 0.4%. Meanwhile, the Dow gained 0.47%, and the Nasdaq, a tech-heavy index, added 0.24%.
The stock of pharmaceutical has risen by 5.15% in the past month, leading the Medical sector's gain of 1.19% and the S&P 500's gain of 4.61%.
The upcoming earnings release of Astrazeneca will be of great interest to investors. The company's earnings report is expected on July 29, 2025. The company is predicted to post an EPS of $1.09, indicating a 10.1% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $14.03 billion, up 8.45% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $4.5 per share and a revenue of $57.71 billion, representing changes of +9.49% and +6.72%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Astrazeneca. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.11% lower. Astrazeneca currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Astrazeneca is at present trading with a Forward P/E ratio of 16.39. This valuation marks a discount compared to its industry average Forward P/E of 19.38.
Meanwhile, AZN's PEG ratio is currently 1.35. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Medical - Biomedical and Genetics industry stood at 1.76 at the close of the market yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Astrazeneca (AZN) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest close session, Astrazeneca (AZN - Free Report) was down 1.38% at $72.66. The stock trailed the S&P 500, which registered a daily gain of 0.4%. Meanwhile, the Dow gained 0.47%, and the Nasdaq, a tech-heavy index, added 0.24%.
The stock of pharmaceutical has risen by 5.15% in the past month, leading the Medical sector's gain of 1.19% and the S&P 500's gain of 4.61%.
The upcoming earnings release of Astrazeneca will be of great interest to investors. The company's earnings report is expected on July 29, 2025. The company is predicted to post an EPS of $1.09, indicating a 10.1% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $14.03 billion, up 8.45% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $4.5 per share and a revenue of $57.71 billion, representing changes of +9.49% and +6.72%, respectively, from the prior year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Astrazeneca. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.11% lower. Astrazeneca currently has a Zacks Rank of #3 (Hold).
In the context of valuation, Astrazeneca is at present trading with a Forward P/E ratio of 16.39. This valuation marks a discount compared to its industry average Forward P/E of 19.38.
Meanwhile, AZN's PEG ratio is currently 1.35. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Medical - Biomedical and Genetics industry stood at 1.76 at the close of the market yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 95, putting it in the top 39% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.